vs

Side-by-side financial comparison of Fastly, Inc. (FSLY) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Fastly, Inc. is the larger business by last-quarter revenue ($172.6M vs $151.7M, roughly 1.1× Tarsus Pharmaceuticals, Inc.). Tarsus Pharmaceuticals, Inc. runs the higher net margin — -5.5% vs -9.0%, a 3.5% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 22.8%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $12.2M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 13.7%).

Fastly, Inc. is an American company based in San Francisco, which describes itself as a cloud computing company. Fastly provides content delivery network services, image optimization, and load balancing services. Fastly's cloud security services include denial-of-service attack protection, bot mitigation, and a web application firewall.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

FSLY vs TARS — Head-to-Head

Bigger by revenue
FSLY
FSLY
1.1× larger
FSLY
$172.6M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+105.6% gap
TARS
128.4%
22.8%
FSLY
Higher net margin
TARS
TARS
3.5% more per $
TARS
-5.5%
-9.0%
FSLY
More free cash flow
TARS
TARS
$729.0K more FCF
TARS
$13.0M
$12.2M
FSLY
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
13.7%
FSLY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FSLY
FSLY
TARS
TARS
Revenue
$172.6M
$151.7M
Net Profit
$-15.5M
$-8.4M
Gross Margin
61.4%
Operating Margin
-8.7%
-5.3%
Net Margin
-9.0%
-5.5%
Revenue YoY
22.8%
128.4%
Net Profit YoY
52.9%
63.8%
EPS (diluted)
$-0.10
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FSLY
FSLY
TARS
TARS
Q4 25
$172.6M
$151.7M
Q3 25
$158.2M
$118.7M
Q2 25
$148.7M
$102.7M
Q1 25
$144.5M
$78.3M
Q4 24
$140.6M
$66.4M
Q3 24
$137.2M
$48.1M
Q2 24
$132.4M
$40.8M
Q1 24
$133.5M
$27.6M
Net Profit
FSLY
FSLY
TARS
TARS
Q4 25
$-15.5M
$-8.4M
Q3 25
$-29.5M
$-12.6M
Q2 25
$-37.5M
$-20.3M
Q1 25
$-39.1M
$-25.1M
Q4 24
$-32.9M
$-23.1M
Q3 24
$-38.0M
$-23.4M
Q2 24
$-43.7M
$-33.3M
Q1 24
$-43.4M
$-35.7M
Gross Margin
FSLY
FSLY
TARS
TARS
Q4 25
61.4%
Q3 25
58.4%
Q2 25
54.5%
Q1 25
53.2%
Q4 24
53.4%
Q3 24
54.5%
Q2 24
55.1%
Q1 24
54.8%
Operating Margin
FSLY
FSLY
TARS
TARS
Q4 25
-8.7%
-5.3%
Q3 25
-18.2%
-12.2%
Q2 25
-24.8%
-21.6%
Q1 25
-26.4%
-33.5%
Q4 24
-24.4%
-36.8%
Q3 24
-29.6%
-52.3%
Q2 24
-35.3%
-81.6%
Q1 24
-34.6%
-136.5%
Net Margin
FSLY
FSLY
TARS
TARS
Q4 25
-9.0%
-5.5%
Q3 25
-18.6%
-10.6%
Q2 25
-25.2%
-19.8%
Q1 25
-27.1%
-32.1%
Q4 24
-23.4%
-34.8%
Q3 24
-27.7%
-48.7%
Q2 24
-33.0%
-81.6%
Q1 24
-32.5%
-129.4%
EPS (diluted)
FSLY
FSLY
TARS
TARS
Q4 25
$-0.10
$-0.17
Q3 25
$-0.20
$-0.30
Q2 25
$-0.26
$-0.48
Q1 25
$-0.27
$-0.64
Q4 24
$-0.23
$-0.57
Q3 24
$-0.27
$-0.61
Q2 24
$-0.32
$-0.88
Q1 24
$-0.32
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FSLY
FSLY
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$361.8M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$929.6M
$343.4M
Total Assets
$1.5B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FSLY
FSLY
TARS
TARS
Q4 25
$361.8M
$417.3M
Q3 25
$342.9M
$401.8M
Q2 25
$321.2M
$381.1M
Q1 25
$307.3M
$407.9M
Q4 24
$295.9M
$291.4M
Q3 24
$308.2M
$317.0M
Q2 24
$311.8M
$323.6M
Q1 24
$329.5M
$298.5M
Total Debt
FSLY
FSLY
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
FSLY
FSLY
TARS
TARS
Q4 25
$929.6M
$343.4M
Q3 25
$937.0M
$335.1M
Q2 25
$942.6M
$332.6M
Q1 25
$957.0M
$342.5M
Q4 24
$965.3M
$224.5M
Q3 24
$969.5M
$237.5M
Q2 24
$981.2M
$252.2M
Q1 24
$991.8M
$275.2M
Total Assets
FSLY
FSLY
TARS
TARS
Q4 25
$1.5B
$562.2M
Q3 25
$1.5B
$534.6M
Q2 25
$1.5B
$495.0M
Q1 25
$1.4B
$500.8M
Q4 24
$1.5B
$377.0M
Q3 24
$1.5B
$376.3M
Q2 24
$1.5B
$376.8M
Q1 24
$1.5B
$349.3M
Debt / Equity
FSLY
FSLY
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FSLY
FSLY
TARS
TARS
Operating Cash FlowLast quarter
$22.4M
$19.3M
Free Cash FlowOCF − Capex
$12.2M
$13.0M
FCF MarginFCF / Revenue
7.1%
8.6%
Capex IntensityCapex / Revenue
5.9%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$65.8M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FSLY
FSLY
TARS
TARS
Q4 25
$22.4M
$19.3M
Q3 25
$28.9M
$18.3M
Q2 25
$25.8M
$-29.4M
Q1 25
$17.3M
$-20.7M
Q4 24
$5.2M
$-22.2M
Q3 24
$5.0M
$-8.7M
Q2 24
$-4.9M
$-14.4M
Q1 24
$11.1M
$-37.8M
Free Cash Flow
FSLY
FSLY
TARS
TARS
Q4 25
$12.2M
$13.0M
Q3 25
$22.9M
$16.3M
Q2 25
$15.9M
$-30.4M
Q1 25
$14.7M
$-21.2M
Q4 24
$251.0K
$-22.3M
Q3 24
$3.0M
$-8.9M
Q2 24
$-6.7M
$-15.4M
Q1 24
$9.5M
$-38.0M
FCF Margin
FSLY
FSLY
TARS
TARS
Q4 25
7.1%
8.6%
Q3 25
14.5%
13.8%
Q2 25
10.7%
-29.6%
Q1 25
10.2%
-27.1%
Q4 24
0.2%
-33.5%
Q3 24
2.2%
-18.6%
Q2 24
-5.1%
-37.8%
Q1 24
7.1%
-137.5%
Capex Intensity
FSLY
FSLY
TARS
TARS
Q4 25
5.9%
4.2%
Q3 25
3.8%
1.6%
Q2 25
6.6%
1.0%
Q1 25
1.8%
0.8%
Q4 24
3.5%
0.1%
Q3 24
1.5%
0.6%
Q2 24
1.3%
2.5%
Q1 24
1.2%
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FSLY
FSLY

Network Services$130.8M76%
Security$35.4M21%
Other$6.4M4%

TARS
TARS

Segment breakdown not available.

Related Comparisons